|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, histone deacetylase inhibitors are already in use for the treatment of MM in combination therapy, and targeted inhibition of FGFR3 (AZD4547) is effective in myeloma cells with t(4;14) translocation.
|
31036508 |
2019 |
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Translocation t(4;14) is observed in about 15% of patients with MM leading to constitutive activation of FGFR3 in two-thirds of these patients.
|
30349651 |
2018 |
|
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The IGH deletions were found in 7 MM analyzed with the FGFR3-IGH probe and all confirmed by the IGH break-apart probe.
|
29040969 |
2017 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
|
27509849 |
2016 |
|
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Protein Expression for Novel Prognostic Markers (Cyclins D1, D2, D3, B1, B2, ITGβ7, FGFR3, PAX5) Correlate With Previously Reported Gene Expression Profile Patterns in Plasma Cell Myeloma.
|
25265432 |
2016 |
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Approximately 15% of patients with multiple myeloma (MM) exhibit a t(4;14) translocation, which often results in constitutive activation of the receptor tyrosine kinase (RTK) fibroblast growth factor receptor 3 (FGFR3).
|
25402977 |
2015 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Chromosomal translocation of FGFR1 occurs in the 8p11 myeloproliferative syndrome and alveolar rhabdomyosarcoma, as with FGFR3 in multiple myeloma and peripheral T-cell lymphoma.
|
23696246 |
2014 |
|
Multiple Myeloma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Fibroblast growth factor receptor 3 interacts with and activates TGFβ-activated kinase 1 tyrosine phosphorylation and NFκB signaling in multiple myeloma and bladder cancer.
|
24466111 |
2014 |
|
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among recurrent IGH translocations in MM, the frequency of t(4;14) (IGH and FGFR3) or t(11;14) (IGH and CCND1) is greater than the frequency of t(14;16) (IGH and MAF).
|
23460268 |
2013 |
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We found that target genes of the most differentially expressed miRNAs are directly involved in the pathogenesis of MM; specifically, the inhibition of hsa-miR-425, hsa-miR-152 and hsa-miR-24, which are all downregulated in h-MM, leads to the overexpression of CCND1, TACC3, MAFB, FGFR3 and MYC, which are the also the oncogenes upregulated by the most frequent IgH chromosomal translocations occurring in nh-MM.
|
23174883 |
2013 |
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.
|
22329352 |
2012 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
As a part of these translational efforts, novel drugs that inhibit oncogenic proteins overexpressed in defined molecular subgroups of the disease, such as FGFR3 and MMSET in t(4;14) MM, are currently being developed.
|
23233602 |
2012 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
From a clinical standpoint, it is critical to identify MM patients carrying the t(4;14) translocation, which is present in 15% of myelomas and is associated with dysregulation of WHSC1/MMSET and often FGFR3.
|
22160056 |
2011 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Ribosomal protein metallopanstimulin-1 impairs multiple myeloma CAG cells growth and inhibits fibroblast growth factor receptor 3.
|
21889435 |
2011 |
|
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The ectopically expressed fibroblast growth factor receptor 3 (FGFR3) and its constitutively active mutations have been detected in patients with multiple myeloma (MM).
|
21273588 |
2011 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that PD173074 and sunitinib are inhibitors of FGFR3 in MM cell lines, and that sunitinib has in vivo activity in a human MM tumour xenograft model.
|
21316102 |
2011 |
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
This suggests that dysregulated FGFR3 expression is likely to be essential at least for the early stages of pathogenesis of MM tumors that have a t(4;14) translocation.
|
20393505 |
2010 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A t(4;14)/IGH-FGFR3 was detected in 28 PCM (11.1%) and 5 MGUS (1.9%; P < 0.001).
|
21156229 |
2010 |
|
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Reciprocal IGH/14q32 translocations are detectable in 55-70% of patients with plasma cell myeloma; e.g., the adverse t(4;14)(p16;q32) fusing the IGH and FGFR3 genes (immunoglobulin heavy chain/fibroblast growth factor receptor 3).
|
20620602 |
2010 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The identification of these overlapping sets of co-modulated tyrosine phosphorylations presents an outline of an FGFR3 network in the MM model and demonstrates the potential for pharmacodynamic monitoring by label-free quantitative phospho-proteomics.
|
19901323 |
2009 |
|
Multiple Myeloma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
|
19147757 |
2009 |
|
Multiple Myeloma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment resistance in multiple myeloma.
|
19331127 |
2009 |
|
Multiple Myeloma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that an endogenous negative regulatory role for the p85-FGFR3 interaction on the Ras/ERK/MAPK pathway may exist in response to FGFR3 activity and identifies a novel therapeutic target for MM.
|
19286672 |
2009 |